In addition to uncovering the role of EBV in the pathogenesis of cHL, these studies indicate that effective blocking of GLS1 and GAC can provide potential treatment against EBV-associated cancers [13]. The gene discussed is GLS; the disease is classic Hodgkin lymphoma.